Viridian Therapeutics, Inc./DE Other Operating Income (Expense), Net
Viridian Therapeutics, Inc./DE (VRDN) reported Other Operating Income (Expense), Net of $156.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherOperatingIncomeExpenseNet · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE other operating income (expense), net for the quarter ending 2026-06-30 was $156.00K.
- Viridian Therapeutics, Inc./DE other operating income (expense), net for the quarter ending 2026-03-31 was -$672.00K.
- Viridian Therapeutics, Inc./DE other operating income (expense), net for the quarter ending 2025-12-31 was -$2.12M.
- Viridian Therapeutics, Inc./DE other operating income (expense), net for the quarter ending 2025-09-30 was $453.00K.
- Viridian Therapeutics, Inc./DE other operating income (expense), net for fiscal 2025 was -$1.66M.
- Viridian Therapeutics, Inc./DE other operating income (expense), net for fiscal 2024 was -$314.00K.
- Viridian Therapeutics, Inc./DE other operating income (expense), net for fiscal 2023 was -$193.00K.
| Period end | Other Operating Income (Expense), Net 3 month | Other Operating Income (Expense), Net 6 month | Other Operating Income (Expense), Net 9 month | Other Operating Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $156.00K 10-Q · filed 2026-08-06 | -$516.00K 10-Q · filed 2026-08-06 | -$2.63M derived: sum of 3 quarters · filed 2026-08-06 | -$2.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$672.00K 10-Q · filed 2026-05-05 | -$2.79M derived: sum of 2 quarters · filed 2026-05-05 | -$2.33M derived: sum of 3 quarters · filed 2026-05-05 | -$2.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.66M derived: sum of 2 quarters · filed 2026-02-26 | -$1.66M derived: sum of 3 quarters · filed 2026-08-06 | -$1.66M 10-K · filed 2026-02-26 |
| 2025-09-30 | $453.00K 10-Q · filed 2025-11-05 | $453.00K derived: sum of 2 quarters · filed 2026-08-06 | $459.00K 10-Q · filed 2025-11-05 | $161.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | -$292.00K derived: sum of 3 quarters · filed 2026-08-06 | -$487.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$36.00K 10-Q · filed 2026-05-05 | -$292.00K derived: sum of 2 quarters · filed 2026-05-05 | -$487.00K derived: sum of 3 quarters · filed 2026-05-05 | |
| 2024-12-31 | -$256.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$451.00K derived: sum of 2 quarters · filed 2026-02-26 | -$314.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$195.00K 10-Q · filed 2025-11-05 | -$58.00K 10-Q · filed 2025-11-05 | ||
| 2023-12-31 | -$193.00K 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |